Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to TNFSF13B/CD257 is a common target in medicine.

When BAFF binds to its receptor, it activates a series of signaling pathways, the most important of which is the NF- κ B (nuclear factor κ B) signaling pathway. Moreover, other signaling pathways such as PI3K / Akt and mTOR may be involved. After the binding of BAFF to its receptor, it eventually activates NF- κ B through the transmission of a series of signaling molecules. NF- κ B is a transcription factor, whose activation promotes the transcription of a range of genes, thereby regulating the proliferation, differentiation, and activation of B cells. BAFF blockade protected against colitis to some extent by relieving inflammation and inhibiting the intestinal NLRP 3 inflammasome and the macrophage NF- κ B signaling-based pathway. BAFF and APRIL have two common receptors, namely, the TNFR cognate transmembrane activator and the Ca 2 + regulator the CAML interactor (TACI), and the B cell maturation antigen. BAFF alone can also be coupled to a third receptor called BAFFR (also known as BR 3 or BLyS receptor). These receptors are normally expressed by immune cells in the B cell lineage. The binding of BAFF or APRIL to its receptor supports the differentiation of B cells and proliferation and upregulation of immunoglobulin production and expression of B cell effector molecules.

Currently, various immune drugs targeting TNFSF13B/CD257 targets are in the updating iteration, and taking the disease alone or in combination with other products has become a new approach with remarkable achievements. The TNFSF13B/CD257 targets have shown important research value and application prospects in both biology and drug research and development. With further research and detection technology advances, TNFSF13B/CD257 target products are also essential in medical research. Alpha Lifetech can provide TNFSF13B/CD257 corresponding products and help each customer's research and development. Alpha Lifetech provides end-to-end biotechnology development solutions, from upstream cell culture optimization to downstream purification scale. Our process is validated through analytical techniques such as HPLC, SDS-PAGE, and mass spectrometry to ensure product consistency and regulatory compliance. By combining cutting-edge biotechnology expertise with flexible service models, we help clients accelerate project research progress and ensure smooth experimentation.